Valeo Pharma and Besins Healthcare partner to bring Utrogestan to women in Canada

Valeo Pharma Inc., a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products, and Besins Healthcare, a global pharmaceutical company world leader in novel therapies for gynecology and andrology, come to a strategic agreement to commercialize Utrogestan (micronised natural progesterone; 200mg capsules) in Canada. Utrogestan is indicated for luteal phase support during in-vitro fertilization (IVF) cycles.

Sunil Sehgal, president, Ascend Therapeutics LLC, a Besins Healthcare company operating in the U.S.A., expresses, “we welcome the opportunity to work closely with Valeo Pharma and look forward to collaborating for a successful launch of Utrogestan in early 2019.”

“Our Specialty pipeline continues to build and we project to launch several new products in Canada over the next 12-18 months.” – Marc Leger 

Under the terms of the agreement with Besins Healthcare, Valeo Pharma is responsible for all aspects of sales, marketing, quality and distribution activities pertaining to Utrogestan 200mg capsules in Canada.

“Besins Healthcare has an international track record of successfully developing, partnering and commercializing Specialty Woman’s Health Products,” says Steve Saviuk, chief executive officer of Valeo Pharma. “We are excited to add this unique strength of micronized progesterone (Utrogestan 200mg capsules) to our Specialty Pharmaceutical portfolio and offer a new choice in a growing area of concern for Canadian families.”

With a focus on neurodegenerative diseases, woman’s health and rare diseases, Valeo Pharma has a growing portfolio of innovative products and a platform to properly manage these products through all stages of commercialization.  Headquartered in Kirkland, Quebec, Valeo Pharma has all capabilities internally to register and market health care solutions for Canadian patients.

“Besins Healthcare has an international track record of successfully developing, partnering and commercializing Specialty Woman’s Health Products. We are excited to add this unique strength of micronized progesterone (Utrogestan 200mg capsules) to our Specialty Pharmaceutical portfolio and offer a new choice in a growing area of concern for Canadian families.” – Steve Saviuk

“As Utrogestan has already been granted marketing approval by Health Canada, we are on track for a 2019 product launch,” adds Marc Leger, chief commercial officer. “Our Specialty pipeline continues to build and we project to launch several new products in Canada over the next 12-18 months.”

Antoine Besins, CEO of Besins Healthcare says, “We are pleased that Utrogestan is being made available to meet patients’ needs in Canada, as in over a hundred countries around the world.”

Be the first to comment

Leave a Reply

Your email address will not be published.


*